Lance Laing

833 total citations
23 papers, 687 citations indexed

About

Lance Laing is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lance Laing has authored 23 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lance Laing's work include PI3K/AKT/mTOR signaling in cancer (6 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Lance Laing is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Lance Laing collaborates with scholars based in United States, Spain and United Kingdom. Lance Laing's co-authors include David E. Draper, Brian T. Cunningham, Thomas C. Gluick, Kathleen B. Hall, Stephen Schulz, Bo Lin, Fengqiu Wang, E W Fine, Cheryl L. Baird and Yanyan Xing and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Molecular Biology and Biochemistry.

In The Last Decade

Lance Laing

22 papers receiving 660 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lance Laing United States 9 486 167 117 109 61 23 687
Eric Alonas United States 14 280 0.6× 143 0.9× 58 0.5× 49 0.4× 42 0.7× 16 727
A. S. M. Kamruzzahan Austria 8 280 0.6× 115 0.7× 159 1.4× 423 3.9× 28 0.5× 8 618
Denise Pollard-Knight United Kingdom 13 513 1.1× 243 1.5× 163 1.4× 62 0.6× 21 0.3× 20 801
Josette Jeusset France 14 992 2.0× 98 0.6× 47 0.4× 95 0.9× 44 0.7× 23 1.3k
Karin Felderer Germany 6 454 0.9× 169 1.0× 68 0.6× 49 0.4× 17 0.3× 8 685
Yongjian Yue China 8 457 0.9× 130 0.8× 56 0.5× 20 0.2× 10 0.2× 14 677
Wilma Bergsma‐Schutter Netherlands 11 627 1.3× 71 0.4× 35 0.3× 134 1.2× 26 0.4× 14 857
Kirstin A. Walther United States 8 464 1.0× 68 0.4× 72 0.6× 413 3.8× 17 0.3× 8 788
Yangang Pan United States 12 299 0.6× 94 0.6× 39 0.3× 123 1.1× 15 0.2× 28 468
Andrea Picco Germany 13 627 1.3× 68 0.4× 22 0.2× 121 1.1× 69 1.1× 19 1.0k

Countries citing papers authored by Lance Laing

Since Specialization
Citations

This map shows the geographic impact of Lance Laing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lance Laing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lance Laing more than expected).

Fields of papers citing papers by Lance Laing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lance Laing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lance Laing. The network helps show where Lance Laing may publish in the future.

Co-authorship network of co-authors of Lance Laing

This figure shows the co-authorship network connecting the top 25 collaborators of Lance Laing. A scholar is included among the top collaborators of Lance Laing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lance Laing. Lance Laing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khan, Salmaan, Stefano Rossetti, Ian A. MacNeil, et al.. (2024). Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway. Molecular Oncology. 19(1). 225–247. 4 indexed citations
2.
3.
Rossetti, Stefano, Salmaan Khan, Ian A. MacNeil, et al.. (2024). Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models. npj Breast Cancer. 10(1). 40–40. 14 indexed citations
4.
5.
6.
Sen, Adrish, Salmaan Khan, Ian A. MacNeil, et al.. (2023). Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.. Journal of Clinical Oncology. 41(6_suppl). 149–149. 2 indexed citations
7.
MacNeil, Ian A., et al.. (2022). Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy. Cell Communication and Signaling. 20(1). 4–4. 2 indexed citations
8.
9.
MacNeil, Ian A., David J. Burns, Benjamin E. Rich, et al.. (2020). New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified. Journal of Cancer Research and Clinical Oncology. 146(3). 605–619. 5 indexed citations
10.
Laing, Lance, et al.. (2020). Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy.. Journal of Clinical Oncology. 38(15_suppl). e18038–e18038. 1 indexed citations
11.
Burns, David J., Benjamin E. Rich, Ian A. MacNeil, et al.. (2017). Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells. BMC Cancer. 17(1). 199–199. 14 indexed citations
12.
Burns, David J., Benjamin E. Rich, Ian A. MacNeil, et al.. (2016). A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity. Oncotarget. 7(48). 78577–78590. 3 indexed citations
13.
Vela, Laura, Peter N. Lowe, Lance Laing, et al.. (2011). Validation of an Optical Microplate Label-Free Platform in the Screening of Chemical Libraries for Direct Binding to a Nuclear Receptor. Assay and Drug Development Technologies. 9(5). 532–548. 4 indexed citations
14.
Cunningham, Brian T. & Lance Laing. (2008). Advantages and application of label-free detection assays in drug screening. Expert Opinion on Drug Discovery. 3(8). 891–901. 34 indexed citations
15.
Cunningham, Brian T. & Lance Laing. (2006). Microplate-based, label-free detection of biomolecular interactions: applications in proteomics. Expert Review of Proteomics. 3(3). 271–281. 72 indexed citations
16.
Cunningham, Brian T., Stephen Schulz, Bo Lin, et al.. (2004). Label-Free Assays on the BIND System. SLAS DISCOVERY. 9(6). 481–490. 205 indexed citations
17.
Laing, Lance & Kathleen B. Hall. (1996). A Model of the Iron Responsive Element RNA Hairpin Loop Structure Determined from NMR and Thermodynamic Data. Biochemistry. 35(42). 13586–13596. 56 indexed citations
18.
Draper, David E., Yanyan Xing, & Lance Laing. (1995). Thermodynamics of RNA unfolding: Stabilization of a ribosomal RNA tertiary structure by thiostrepton and ammonium ion. Journal of Molecular Biology. 249(2). 231–238. 33 indexed citations
19.
Laing, Lance, Thomas C. Gluick, & David E. Draper. (1994). Stabilization of RNA Structure by Mg Ions. Journal of Molecular Biology. 237(5). 577–587. 135 indexed citations
20.
Laing, Lance & David E. Draper. (1994). Thermodynamics of RNA Folding in a Conserved Ribosomal RNA Domain. Journal of Molecular Biology. 237(5). 560–576. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric Alonas Breakdown of academic impact, for papers by A. S. M. Kamruzzahan Breakdown of academic impact, for papers by Denise Pollard-Knight Breakdown of academic impact, for papers by Josette Jeusset Breakdown of academic impact, for papers by Karin Felderer Breakdown of academic impact, for papers by Yongjian Yue Breakdown of academic impact, for papers by Wilma Bergsma‐Schutter Breakdown of academic impact, for papers by Kirstin A. Walther Breakdown of academic impact, for papers by Yangang Pan Breakdown of academic impact, for papers by Andrea Picco
Rankless by CCL
2026